Index RUT
P/E -
EPS (ttm) -0.58
Insider Own 41.31%
Shs Outstand 61.54M
Perf Week 6.82%
Market Cap 120.85M
Forward P/E -
EPS next Y -0.73
Insider Trans -32.37%
Shs Float 39.40M
Perf Month 7.46%
Income -36.25M
PEG -
EPS next Q -0.18
Inst Own 49.86%
Short Float / Ratio 26.64% / 10.33
Perf Quarter -78.44%
Sales 0.00M
P/S -
EPS this Y -183.85%
Inst Trans 2.11%
Short Interest 10.50M
Perf Half Y -85.07%
Book/sh -17.74
P/B -
EPS next Y -11.12%
ROA -7.37%
Target Price 6.67
Perf Year -82.59%
Cash/sh 5.90
P/C 0.30
EPS next 5Y -
ROE -
52W Range 1.12 - 14.19
Perf YTD -73.76%
Dividend -
P/FCF -
EPS past 5Y -
ROI -
52W High -87.32%
Beta 1.19
Dividend % -
Quick Ratio 19.37
Sales past 5Y 0.00%
Gross Margin -
52W Low 60.71%
ATR 0.27
Employees 87
Current Ratio 19.37
Sales Q/Q -
Oper. Margin 0.00%
RSI (14) 46.51
Volatility 13.86% 18.01%
Optionable Yes
Debt/Eq -
EPS Q/Q 8.00%
Profit Margin -
Rel Volume 0.35
Prev Close 1.81
Shortable Yes
LT Debt/Eq -
Earnings Nov 14 BMO
Payout -
Avg Volume 1.02M
Price 1.80
Recom 1.50
SMA20 9.04%
SMA50 -22.87%
SMA200 -78.69%
Volume 356,596
Change -0.55%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-25-23 Initiated
BTIG Research
Buy
$16
Dec-21-22 Initiated
Jefferies
Buy
$15
Nov-10-22 Initiated
Morgan Stanley
Equal-Weight
$13
Oct-18-22 Initiated
UBS
Buy
$18
Oct-14-22 Initiated
Citigroup
Buy
$16
Sep-23-22 Initiated
BofA Securities
Buy
$14
Sep-02-22 Initiated
Evercore ISI
Outperform
Nov-30-23 06:05AM
Nov-24-23 06:40AM
Nov-21-23 06:05AM
Nov-17-23 01:38PM
Nov-16-23 09:35AM
07:04AM
Loading…
Nov-14-23 07:04AM
06:05AM
Nov-13-23 05:02PM
Oct-30-23 04:12PM
Oct-17-23 09:35AM
Oct-16-23 02:50PM
Oct-12-23 03:05PM
Sep-06-23 12:14PM
(American City Business Journals)
Sep-05-23 06:05AM
Aug-31-23 10:33AM
01:16PM
Loading…
Aug-29-23 01:16PM
(American City Business Journals)
Aug-11-23 02:21PM
(American City Business Journals)
Aug-10-23 04:10PM
Jul-18-23 06:05AM
Jul-17-23 06:05AM
Jun-13-23 12:05PM
Jun-01-23 04:05PM
May-11-23 04:01PM
May-04-23 06:05AM
Apr-25-23 02:00PM
Mar-28-23 04:12PM
Mar-03-23 06:05AM
Jan-11-23 07:48AM
Jan-10-23 04:05PM
Dec-27-22 11:05AM
08:46AM
Loading…
08:46AM
Dec-22-22 06:05AM
Nov-16-22 11:22AM
Nov-14-22 06:05AM
Nov-11-22 04:05PM
Nov-03-22 06:05AM
Oct-14-22 12:00PM
Sep-23-22 06:15AM
Sep-08-22 06:05AM
Aug-31-22 06:05AM
Aug-11-22 05:30PM
10:01AM
Jul-20-22 08:00AM
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient's own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Palihapitiya Chamath Former 10% Owner Nov 19 Sale 1.31 7,256,367 9,498,584 0 Nov 21 06:30 AM Palihapitiya Chamath 10% Owner Nov 17 Sale 1.19 258,400 308,400 5,183,367 Nov 17 09:00 PM Palihapitiya Chamath 10% Owner Nov 16 Sale 1.22 212,100 259,398 5,441,767 Nov 17 09:00 PM Palihapitiya Chamath 10% Owner Nov 15 Sale 1.49 282,300 420,147 5,653,867 Nov 17 09:00 PM Palihapitiya Chamath 10% Owner Nov 14 Sale 1.50 306,200 459,086 5,936,167 Nov 14 09:15 PM Palihapitiya Chamath 10% Owner Nov 13 Sale 1.57 88,700 139,676 6,242,367 Nov 14 09:15 PM Palihapitiya Chamath 10% Owner Nov 10 Sale 1.61 85,900 138,411 6,331,067 Nov 14 09:15 PM Palihapitiya Chamath 10% Owner Nov 09 Sale 1.68 95,900 160,700 6,416,967 Nov 14 09:15 PM Palihapitiya Chamath 10% Owner Nov 08 Sale 1.66 59,000 97,763 6,512,867 Nov 08 09:00 PM Palihapitiya Chamath 10% Owner Nov 07 Sale 1.59 71,233 113,367 6,571,867 Nov 08 09:00 PM Palihapitiya Chamath 10% Owner Nov 06 Sale 1.56 79,600 123,818 6,643,100 Nov 08 09:00 PM Palihapitiya Chamath 10% Owner Nov 03 Sale 1.73 148,300 256,470 6,722,700 Nov 03 09:00 PM Palihapitiya Chamath 10% Owner Nov 02 Sale 1.73 133,700 231,956 6,871,000 Nov 03 09:00 PM Palihapitiya Chamath 10% Owner Nov 01 Sale 1.62 123,400 199,674 7,004,700 Nov 03 09:00 PM Palihapitiya Chamath 10% Owner Oct 31 Sale 1.69 141,900 239,300 7,128,100 Oct 31 09:30 PM Palihapitiya Chamath 10% Owner Oct 30 Sale 1.65 157,000 259,537 7,270,000 Oct 31 09:30 PM Palihapitiya Chamath 10% Owner Oct 27 Sale 1.59 92,500 146,677 7,427,000 Oct 31 09:30 PM Palihapitiya Chamath 10% Owner Oct 26 Sale 1.80 77,960 140,577 7,519,500 Oct 26 09:00 PM Palihapitiya Chamath 10% Owner Oct 25 Sale 1.76 67,213 118,382 7,597,460 Oct 26 09:00 PM Palihapitiya Chamath 10% Owner Oct 24 Sale 1.75 176,300 308,613 7,664,673 Oct 26 09:00 PM Palihapitiya Chamath 10% Owner Oct 23 Sale 1.83 160,300 293,429 7,840,973 Oct 23 09:00 PM Palihapitiya Chamath 10% Owner Oct 20 Sale 1.92 87,200 167,834 8,001,273 Oct 23 09:00 PM Palihapitiya Chamath 10% Owner Oct 19 Sale 2.19 200,000 438,700 8,088,473 Oct 23 09:00 PM Palihapitiya Chamath 10% Owner Oct 18 Sale 2.28 125,100 285,403 8,288,473 Oct 18 09:00 PM Palihapitiya Chamath 10% Owner Oct 17 Sale 2.83 106,400 301,357 8,413,573 Oct 18 09:00 PM Palihapitiya Chamath 10% Owner Oct 16 Sale 2.87 215,543 618,630 8,519,973 Oct 18 09:00 PM Palihapitiya Chamath 10% Owner Oct 13 Sale 2.67 250,000 667,525 8,735,516 Oct 13 09:30 PM Palihapitiya Chamath 10% Owner Oct 12 Sale 2.69 161,863 436,007 8,985,516 Oct 13 09:30 PM Palihapitiya Chamath 10% Owner Oct 11 Sale 3.84 75,000 288,285 9,147,379 Oct 13 09:30 PM Palihapitiya Chamath 10% Owner Oct 10 Sale 4.34 75,000 325,162 9,222,379 Oct 10 09:32 PM Palihapitiya Chamath 10% Owner Oct 09 Sale 4.20 75,000 315,225 9,297,379 Oct 10 09:32 PM Palihapitiya Chamath 10% Owner Oct 06 Sale 4.48 75,000 336,360 9,372,379 Oct 10 09:32 PM Palihapitiya Chamath 10% Owner Oct 05 Sale 4.76 52,621 250,718 9,447,379 Oct 10 09:32 PM Palihapitiya Chamath 10% Owner Sep 19 Sale 5.47 1,700,000 9,299,000 2,073,000 Sep 21 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite